MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.70
+0.18
+3.26%
After Hours: 5.70 0 0.00% 17:36 11/25 EST
OPEN
5.57
PREV CLOSE
5.52
HIGH
5.77
LOW
5.50
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
27.84
52 WEEK LOW
4.780
MARKET CAP
188.23M
P/E (TTM)
-3.4850
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing. Dr. White brings over 20 years of experience overseeing the complexities of the chemistry manufacturing and controls process. “Nicole will be a tremendous asset to Assembly Bio as we continue to progress our clinical development efforts, and we are thrilled to welcome her to the company,” said John McHutchison, AO, MD, Chief Executive Officer and President. “She is an established leader with proven success guiding programs throughout the entirety of the clinical lifecycle and ultimately to production of the commercial supply. Nicole will play a key strategic role in the advancement of our pipeline of core inhibitors, including vebicorvir, which we are preparing for Phase 3 studies next year.”"I am excited to join the leadership team at Assembly Bio and to work alongside this group of world-class experts in virology,” said Dr. White. “The potential for core inhibitors to improve outcomes for people with HBV is something that I have followed with great interest, and I am eager to apply my experience and strong technical background to support the company’s commitment to bring new and long overdue treatment options to patients with chronic HBV.”Prior to joining Assembly Bio, Dr. White headed Process Chemistry at Gossamer Bio and led chemistry, manufacturing and controls (CMC) for multiple early- and late-stage programs in development. Prior to that she held progressive leadership roles at Gilead Sciences to advance multiple programs from Phase 1 through commercial launch and helped guide the drug substance manufacturing and global outsourcing strategy. While at Gilead, Dr. White contributed to the development and commercial launch of multiple antiviral programs including Harvoni®, Vemlidy® and Vosevi®. She obtained a PhD in Organic Chemistry from the University of California, Irvine and a BS in Chemistry from the University of California, San Diego.About Assembly Biosciences Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.Forward-Looking Statements The information in this press release contains forward-looking statements regarding future events, including statements about the therapeutic potential of our HBV product candidates. Certain forward-looking statements may be identified by reference to a future period or by use of forward-looking terminology such as “will,” “advance,” and “progress.” Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio's filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Investor Contact Assembly Biosciences, Inc. Lauren Glaser Senior Vice President, Investor Relations and Corporate Affairs (415) 521-3828 lglaser@assemblybio.comMedia Contact Sam Brown Inc. Audra Friis (917) 519-9577 ASMBMedia@sambrown.com
GlobeNewswire · 11/17 13:00
Assembly Bio inks deal with Door Pharmaceuticals to develop HBV core protein modulators
Assembly Biosciences (ASMB) and Door Pharmaceuticals have signed an exclusive, two-year collaboration and option agreement focused on the development of a class of hepatitis B virus ((HBV)) core protein modulators.Under
Seekingalpha · 11/16 13:35
Assembly Biosciences, Door Pharmaceuticals Sign Collaboration, Option Agreement To Develop A Novel Class Of HBV Core Protein Modulators
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly
Benzinga · 11/16 13:13
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with viral nucleic acid including cccDNA transcription, providing a strong complement to Assembly Bio’s current portfolio. Under the terms of the agreement, Door Pharmaceuticals will build upon its previous efforts to lead and conduct new discovery research, which will be funded by Assembly Bio. In return for an up-front payment and success-based milestones and royalties, Assembly Bio will be granted an exclusive option to license compounds arising from the collaboration and will be responsible for the continued development and commercialization of optioned compounds. Financial details were not disclosed.“Door Pharmaceuticals was established by our co-founder, Adam Zlotnick, whose research led to the successful discovery of the core inhibitor candidates that comprise Assembly Bio’s clinical program,” said William Delaney, PhD, Chief Scientific Officer, Virology of Assembly Biosciences. “Adam is a true innovator, and this collaboration is a natural continuation of our work together. We’re excited to build upon our current pipeline of HBV core inhibitors with additional contributions from a science-driven company that shares our passion and focus for bringing new treatment options to patients facing HBV.”“I’m thrilled at the opportunity to once again contribute to the advancement of Assembly Bio’s core inhibitor platform under this new collaboration,” said Adam Zlotnick, PhD, Founder of Door Pharmaceuticals. “There is a clear mechanistic rationale for the potential role that core inhibitors can play in the treatment of HBV, and it is our hope and belief that the complementary mechanisms of action of these core protein modulators will offer an important therapeutic pathway towards HBV cure.”About HBV Chronic hepatitis B virus (HBV) infection is a debilitating disease of the liver that afflicts over 250 million people worldwide with up to 90 million people in China, as estimated by the World Health Organization. HBV is a global epidemic that affects more people than hepatitis C virus (HCV) and HIV infection combined—with a higher morbidity and mortality rate. HBV is a leading cause of chronic liver disease and need for liver transplantation, and up to one million people worldwide die every year from HBV-related causes.The current standard of care for patients with chronic HBV infection is life-long suppressive treatment with medications that reduce, but do not eliminate, the virus, resulting in very low cure rates. There is a significant unmet need for new therapies to treat HBV.About Assembly Biosciences Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly Bio’s fully integrated platform, including a robust process for strain identification and selection, GMP manufacturing expertise and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.About Door Pharmaceuticals Door Pharmaceuticals was founded in 2018 by leading HBV researcher, Adam Zlotnick, PhD, a professor of molecular and cellular biochemistry at Indiana University; he is also a fellow of the American Academy of Microbiology and of the AAAS. The company is focused on research of virus structural proteins to discover new classes of inhibitors. The company is initially focused on HBV, with the vision to realize the potential for novel therapeutics for other viruses.Forward-Looking Statements The information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: the Door collaboration may not yield any novel assets and we may not exercise our option with respect to any collaboration compounds; Assembly Bio’s ability to initiate and complete clinical trials involving its HBV therapeutic product candidates in the currently anticipated timeframes; safety and efficacy data from clinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data presented at conferences may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio may not observe sustained virologic response in patients who stop therapy in Study 211; Assembly Bio’s ability to maintain financial resources necessary to continue its clinical trials and fund business operations; any impact that the spread of the coronavirus and resulting COVID-19 pandemic may have on Assembly Bio’s business and operations, including initiation and continuation of its clinical trials or timing of discussions with regulatory authorities; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts Assembly Biosciences, Inc. Lauren Glaser Senior Vice President, Investor Relations and Corporate Affairs (415) 521-3828 lglaser@assemblybio.comMedia Contact Sam Brown Inc. Audra Friis (917) 519-9577 ASMBMedia@sambrown.com
GlobeNewswire · 11/16 13:00
Mid-Afternoon Market Update: Nasdaq Turns Positive; Global Blood Therapeutics Shares Drop Following Q3 Results
Toward the end of trading Friday, the Dow traded down 0.18% to 28,339.69 while the NASDAQ rose 0.16% to 11,910.11. The S&P also rose, gaining 0.03% to 3,511.63.
Benzinga · 11/06 19:31
ACB, TLRY, AAOI and MAXR among midday movers
Gainers: Aurora Cannabis (ACB) +75%.Sundial Growers (SNDL) +57%.Modine Manufacturing (MOD) +41%.Akerna (KERN) +40%.Tilray (TLRY) +40%.Cooper-Standard (CPS) +35%.Mogo (MOGO) +32%.OrganiGram (OGI) +29%.Glu Mobile (GLUU) +28%.FTS International (FTSI) +21%.Losers: Assembly Biosciences (ASMB) -68%.Global Blood Therapeutics (GBT) -36%.Anavex
Seekingalpha · 11/06 17:42
Mid-Day Market Update: Crude Oil Down Over 4%; Modine Manufacturing Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.23% to 28,324.90 while the NASDAQ fell 0.09% to 11,880.69. The S&P also fell, dropping 0.07% to 3,507.96.
Benzinga · 11/06 17:35
Why Assembly Biosciences Stock Is Trading Lower Today
Assembly Biosciences (NASDAQ: ASMB) shares are trading lower on Friday after the company announced its HBV field core inhibitor combination study did not achieve endpoints.
Benzinga · 11/06 17:13
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ASMB. Analyze the recent business situations of Assembly through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ASMB stock price target is 22.60 with a high estimate of 45.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 174
Institutional Holdings: 32.48M
% Owned: 98.35%
Shares Outstanding: 33.02M
TypeInstitutionsShares
Increased
32
1.72M
New
32
1.88M
Decreased
44
3.10M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Non-Executive Chairman/Independent Director
William Ringo
President/Chief Executive Officer/Director
John McHutchison
Chief Financial Officer
Thomas Russo
Chief Financial Officer
Thomas Joseph Russo
Senior Vice President/Chief Scientific Officer
Jacqueline Papkoff
Senior Vice President
David Houck
Senior Vice President
Steven Knox
Senior Vice President
Nicole White
Chief Scientific Officer
William Delaney
Other
Jason Okazaki
Other
Luisa Stamm
Independent Director
Anthony Altig
Independent Director
Gina Consylman
Independent Director
Richard DiMarchi
Independent Director
Myron Holubiak
Independent Director
Helen Kim
Independent Director
Alan Lewis
Independent Director
Susan Mahony
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ASMB
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Assembly Biosciences Inc stock information, including NASDAQ:ASMB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ASMB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ASMB stock methods without spending real money on the virtual paper trading platform.